Evaluating an Investigative Drug Letermovir (Prevymis) in Adults with Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV)
Recruiting
40 years - 99 years
All
15 participants needed
1 Location
Brief description of study
The purpose of this study is to test letermovir when given to people who have both well-controlled HIV infection and asymptomatic CMV infection. This study will also gather data on the effectiveness of letermovir to reduce inflammation when compared to no anti-CMV study treatment. In addition, the study will collect information on whether you experience any side effects from the study drug.
The study will last for about 1 year and 2 months (about 11 months on either letermovir or no anti-CMV study treatment and then about another 3 months of follow-up).
Compensation up to $825.
Detailed description of study
The purpose of this study is to test letermovir when given to people who have both well-controlled HIV infection and asymptomatic CMV infection. This study will also gather data on the effectiveness of letermovir to reduce inflammation when compared to no anti-CMV study treatment. In addition, the study will collect information on whether you experience any side effects from the study drug.
The study will last for about 1 year and 2 months (about 11 months on either letermovir or no anti-CMV study treatment and then about another 3 months of follow-up).
Compensation up to $825.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research,Human Immunodeficiency Virus,HIV-1,HIV,Asymptomatic Cytomegalovirus,CMV
-
Age: 40 years - 99 years
-
Gender: All
Participants Age 40+. Diagnosed with both HIV (the virus that causes AIDS) and a positive antibody test for cytomegalovirus (CMV) (a common virus that can infect almost anyone).
Updated on
04 Aug 2024.
Study ID: 851174
Find a site
,
Your Information has been sent successfully.
Send a message
Enter your contact details to connect with study team
Primary Contact
